tetano
Editor, Senior Moderator
Rev Esp Geriatr Gerontol. 2018 Aug 11. pii: S0211-139X(18)30591-2. doi: 10.1016/j.regg.2018.06.004. [Epub ahead of print]
[h=1][Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine. Positioning report].[/h] [Article in Spanish]
L?pez Trigo JA[SUP]1[/SUP], L?pez Mongil R[SUP]2[/SUP], Mariano L?zaro A[SUP]3[/SUP], Mato Cha?n G[SUP]4[/SUP], Moreno Villajos N[SUP]5[/SUP], Ramos Cordero P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a significant health problem, particularly in those persons susceptible to having associated complications, older people, children less than 2 years, patients with chronic diseases, immunocompromised patients, and pregnant women. But influenza also has a large impact on the health system, with an increase in the healthcare demand and a spectacular increase in outpatient visits, overloading the emergency and hospital services. During epidemic outbreaks, the hospital admission rates of people over 65 years are at a maximum, and the mortality notified for the 2017/2018 influenza season was 960 deaths. The seasonal anti-influenza vaccine is the method with a better cost-effective ratio of primary prevention of influenza, reducing associated respiratory diseases, the number of hospital admissions, and deaths in high risk individuals, as well as work absenteeism in adults. In the last few years, influenza B has received little attention in the scientific literature, although in the periods between epidemics influenza B can be one of the main causes of seasonal epidemics, causing considerable morbidity and mortality and an increase in costs. The quadrivalent vaccine has a second-line immunological protection against influenza B, and according to a critical review of the scientific literature, it provides wider protection without affecting immunogenicity of the other three vaccine strains common to the trivalent and tetravalent vaccine. The quadrivalent vaccine is cost-effective in reducing the number of influenza cases, and is always a worthwhile intervention, with a significant cost saving for the health system and for society, by reducing the hospital admission rates and mortality associated with the complications of influenza. Supplement information: This article is part of a supplement entitled 'Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine' which is sponsored by Sanofi-Aventis, S.A.
[h=4]KEYWORDS:[/h] Cost-benefit; Coste-beneficio; Flu infection; Flu vaccination; Immunosenescence; Infecci?n gripal; Inmunosenescencia; Quadrivalent immunogenicity; Tetravalente inmunogenicidad; Vacunaci?n antigripal
PMID: 30107941 DOI: 10.1016/j.regg.2018.06.004
[h=1][Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine. Positioning report].[/h] [Article in Spanish]
L?pez Trigo JA[SUP]1[/SUP], L?pez Mongil R[SUP]2[/SUP], Mariano L?zaro A[SUP]3[/SUP], Mato Cha?n G[SUP]4[/SUP], Moreno Villajos N[SUP]5[/SUP], Ramos Cordero P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a significant health problem, particularly in those persons susceptible to having associated complications, older people, children less than 2 years, patients with chronic diseases, immunocompromised patients, and pregnant women. But influenza also has a large impact on the health system, with an increase in the healthcare demand and a spectacular increase in outpatient visits, overloading the emergency and hospital services. During epidemic outbreaks, the hospital admission rates of people over 65 years are at a maximum, and the mortality notified for the 2017/2018 influenza season was 960 deaths. The seasonal anti-influenza vaccine is the method with a better cost-effective ratio of primary prevention of influenza, reducing associated respiratory diseases, the number of hospital admissions, and deaths in high risk individuals, as well as work absenteeism in adults. In the last few years, influenza B has received little attention in the scientific literature, although in the periods between epidemics influenza B can be one of the main causes of seasonal epidemics, causing considerable morbidity and mortality and an increase in costs. The quadrivalent vaccine has a second-line immunological protection against influenza B, and according to a critical review of the scientific literature, it provides wider protection without affecting immunogenicity of the other three vaccine strains common to the trivalent and tetravalent vaccine. The quadrivalent vaccine is cost-effective in reducing the number of influenza cases, and is always a worthwhile intervention, with a significant cost saving for the health system and for society, by reducing the hospital admission rates and mortality associated with the complications of influenza. Supplement information: This article is part of a supplement entitled 'Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine' which is sponsored by Sanofi-Aventis, S.A.
[h=4]KEYWORDS:[/h] Cost-benefit; Coste-beneficio; Flu infection; Flu vaccination; Immunosenescence; Infecci?n gripal; Inmunosenescencia; Quadrivalent immunogenicity; Tetravalente inmunogenicidad; Vacunaci?n antigripal
PMID: 30107941 DOI: 10.1016/j.regg.2018.06.004